

AMENDMENT UNDER 37 C.F.R. § 1.111  
Application No.: 10/534,353

Attorney Docket No.: Q87237

**AMENDMENTS TO THE SPECIFICATION**

**Please delete the Abstract and insert the following Abstract shown on a separate sheet.**

### **ABSTRACT**

The present invention relates to a method for the preparation of paclitaxel solid dispersion by using the supercritical fluid process and paclitaxel solid dispersion prepared thereby, the paclitaxel solid dispersion being highly homogeneous and showing an improved solubility, thereby being effectively used for the preparation of paclitaxel injection and oral preparation having a high bioavailability.

**Please replace the paragraph [0028] with the following new paragraph:**

The hydrophilic polymer employable as an additive in the present invention includes, not but limited to, hydroxymethylcellulose (HPMC), polyvinylpyrrolidone, hydroxypropylcellulose (HPC), hydroxyethylcellulose (HEC), and (meth)acrylate polymer, (meth)acrylic acid polymer and a copolymer thereof (e.g., EUDRAGIT®, distributed by Degussa)~~Eudragit~~, preferably hydroxypropylcellulose. The hydrophilic polymer may be suitably selected based on the solution's viscosity to be sprayed and its water solubility. For example, when a solid dispersion is not formed due to the presence of a excessive amount of a surfactant in the liquid phase during the supercritical fluid treatment, it is desirable to increase the amount of HPMC. It is preferable to employ the hydrophilic polymer in the amount ranging from 0.1 to 20 weight part, more preferably 1 to 10 weight part based on 1 weight part of paclitaxel.